These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2644580)

  • 1. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.
    Foster NL; Aldrich MS; Bluemlein L; White RF; Berent S
    Neurology; 1989 Feb; 39(2 Pt 1):257-61. PubMed ID: 2644580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinergic approaches to the treatment of progressive supranuclear palsy.
    Litvan I
    J Neural Transm Suppl; 1994; 42():275-81. PubMed ID: 7964692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pedunculopontine tegmentum cholinergic loss leads to a progressive decline in motor abilities and neuropathological changes resembling progressive supranuclear palsy.
    MacLaren DAA; Ljungberg TL; Griffin ME; Clark SD
    Eur J Neurosci; 2018 Dec; 48(12):3477-3497. PubMed ID: 30339310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
    Mouradian MM; Mohr E; Williams JA; Chase TN
    Neurology; 1988 Apr; 38(4):606-8. PubMed ID: 3281057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic systems in progressive supranuclear palsy.
    Warren NM; Piggott MA; Perry EK; Burn DJ
    Brain; 2005 Feb; 128(Pt 2):239-49. PubMed ID: 15649952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the cholinergic agonist RS 86 on normal sleep: sex and age effects.
    Riemann D; Joy D; Höchli D; Lauer C; Zulley J; Berger M
    Psychiatry Res; 1988 May; 24(2):137-47. PubMed ID: 3406234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic drugs as diagnostic and therapeutic tools in affective disorders.
    Berger M; Riemann D; Krieg C
    Acta Psychiatr Scand Suppl; 1991; 366():52-60. PubMed ID: 1897376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of RS 86, an orally active cholinergic agonist, on sleep in man.
    Spiegel R
    Psychiatry Res; 1984 Jan; 11(1):1-13. PubMed ID: 6369363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy.
    Sixel-Döring F; Schweitzer M; Mollenhauer B; Trenkwalder C
    Sleep Med; 2009 Apr; 10(4):407-15. PubMed ID: 18945638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cholinergic REM induction test with RS 86 after scopolamine pretreatment in healthy subjects.
    Riemann D; Hohagen F; Fleckenstein P; Schredl M; Berger M
    Psychiatry Res; 1991 Sep; 38(3):247-60. PubMed ID: 1754637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.
    Hollander E; Davidson M; Mohs RC; Horvath TB; Davis BM; Zemishlany Z; Davis KL
    Biol Psychiatry; 1987 Sep; 22(9):1067-78. PubMed ID: 3651528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.
    Bruno G; Mohr E; Gillespie M; Fedio P; Chase TN
    Arch Neurol; 1986 Jul; 43(7):659-61. PubMed ID: 3524514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sleepless Night and Day, the Plight of Progressive Supranuclear Palsy.
    Walsh CM; Ruoff L; Walker K; Emery A; Varbel J; Karageorgiou E; Luong PN; Mance I; Heuer HW; Boxer AL; Grinberg LT; Kramer JH; Miller BL; Neylan TC
    Sleep; 2017 Nov; 40(11):. PubMed ID: 29029214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT).
    Wettstein A; Spiegel R
    Psychopharmacology (Berl); 1984; 84(4):572-3. PubMed ID: 6441959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep, age, depression and the cholinergic REM induction test with RS 86.
    Riemann D; Berger M
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 May; 16(3):311-6. PubMed ID: 1589588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idazoxan treatment in progressive supranuclear palsy.
    Ghika J; Tennis M; Hoffman E; Schoenfeld D; Growdon J
    Neurology; 1991 Jul; 41(7):986-91. PubMed ID: 1676832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy.
    Litvan I; Phipps M; Pharr VL; Hallett M; Grafman J; Salazar A
    Neurology; 2001 Aug; 57(3):467-73. PubMed ID: 11502915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REM sleep behavior disorder in patients with guadeloupean parkinsonism, a tauopathy.
    De Cock VC; Lannuzel A; Verhaeghe S; Roze E; Ruberg M; Derenne JP; Willer JC; Vidailhet M; Arnulf I
    Sleep; 2007 Aug; 30(8):1026-32. PubMed ID: 17702273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?
    Blin J; Mazetti P; Mazoyer B; Rivaud S; Ben Ayed S; Malapani C; Pillon B; Agid Y
    Brain; 1995 Dec; 118 ( Pt 6)():1485-95. PubMed ID: 8595479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic and noradrenergic neurotransmission: impact on REM sleep regulation in healthy subjects and depressed patients.
    Riemann D; Hohagen F; Fritsch-Montero R; Krieger S; Gann H; Dressing H; Muller W; Berger M
    Acta Psychiatr Belg; 1992; 92(3):151-71. PubMed ID: 1345430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.